الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
Overactive bladder was recently defined by the (ICS) as “urgency, with or without urge incontinence, usually with nocturia with no proven pathology. The severity of OAB symptoms can be estimated from 24 hours voiding diary for one week stressing on the number of frequency, nocturia, urgency attacks, incontinence episodes and recording how they bother and affect patient’s lifestyle.
Overactive bladder is a common disease among females. About I0-15% of adult women have idiopathic OAB and 5-10% experience urge incontinence.
According to International clinical practice guidelines recommend patient education, lifestyle advice and bladder training for the initial management of OAB that will act as First-line treatment (Behavioral therapies). Oral antimuscarinic (anticholinergic) agents are recommended if first line measures fail.
This study aimed to compare between Soflienacin10mg per day and Tolterodine 4mg per day in the management of OAB according to their efficacy in the treatment, also according to their side effects to the patients. Number of patients were 50 divided into two equal groups 25 patients in each one (group I received (Solifenacin 10mg daily and group II received Tolterodine4 mg daily).
Evaluation was done by OAB score, and filling cystometery study which both were done pre-and post-treatment (3 months).
A urinalysis should be conducted for all patients with OAB symptoms.
The results showed that day time frequency was more reduced with group I (Solifenacin significantly with p value <0.001, night time frequency was more reduced and improved in both groups but more with group I p value <0.001, the reduction in urgency symptoms severity showed more reduction in group I (61.5%) with no significant difference in between both groups. Also urge episodes improved in both groups more in group I p value <0.001 but still significantly improved in symptoms severity in group II. When comparing the effect on patients daily life activity and the perception of bladder control. We found more improved in group I p value <0.001. Reduction of OAB scores was observed significantly after treatment in both groups. group I (Solifenacin↓58.70 ± 6.7) group II (Tolterodine↓35.33 ± 8.4) which means that the reduction of score in group 1 was more obvious with more improvement in symptoms and more bladder control (p value <0.001).
Cystometry show